Current Research on Tuberculosis Prevention, Treatment, Care and Drugs

Dear Colleagues,

Despite decades of work around the world to reduce its effects, TB remains an important global issue. In both high-burden and low-burden countries, the COVID-19 pandemic has affected the ways that TB and other infectious diseases (but also non-communicable diseases) are found, prevented, and treated. Without treatment, about half of the people with tuberculosis will die. However, with new drugs, especially for multidrug-resistant TB, about 85% of people can be cured.

Multisectoral efforts to address Tb risk factors, such as poverty, undernourishment, HIV infection, smoking, diabetes, and lack of access to health care, can reduce the number of people who become infected and ill, and therefore the number of people who die from tuberculosis.

In this ongoing context, current research on its prevention, treatment, and care is crucial to reducing the TB burden and improving the outcomes of patients, and it is also crucial to share this research with your worldwide colleagues.

For this Special Issue, manuscripts that cover all areas of TB prevention, diagnosis, management, and therapy are encouraged. We are interested in either reviews (literature reviews or systematic reviews), prospective or retrospective studies, or case studies.

Manuscripts that address the following topics are also welcome:

1. Mycobacterium tuberculosis surveillance and pathogenesis;
2. Experience with MDR-TB treatment;
3. Risk factors for tuberculosis and latent TB infection (LTBI);
4. Non-tuberculous mycobacteria (NTM);
5. Vulnerable populations (migrants, homeless people);
6. Epidemiology of tuberculosis;
7. Tuberculosis in immunocompetent and immunocompromised people;
8. Both communicable diseases and non-communicable diseases related to TB presentation and outcome.

Dr. Giuseppina De Iaco
Prof. Dr. Francesco Di Gennaro
Dr. Francesco Vladimiro Segala
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• tuberculosis
• epidemiology
• multidrug-resistant TB
• non-tuberculous mycobacteria
• Mycobacterium tuberculosis